Alzheimer’s disease (AD) has for decades been one of the most stubborn challenges in neuroscience and drug development. Regulatory successes like Biogen Inc (NASDAQ:BIIB, XETRA:IDP)’s Leqembi and Eli Lilly and Co (NYSE:LLY)’s Kisunla have been limited to slowing decline, not restoring lost neurological function. That long-held limitation is now being questioned, at least at the preclinical level.
A new study published in Cell Reports Medicine suggests that advanced Alzheimer’s pathology can be not only halted but reversed in animal models by restoring proper cellular energy balance in the brain. The findings — led by researchers at Case Western Reserve University, University Hospitals Cleveland Medical Center (UH) and the Louis Stokes Cleveland VA Medical Center — could upend how scientists think about treating AD, potentially moving the field from disease modification to disease reversal.
Energy, NAD+ and Alzheimer’s: A new target emerges
Rather than directly targeting amyloid plaques or tau tangles — the traditional pathological hallmarks of Alzheimer’s — the team focused on a more fundamental driver of cell health: the molecule nicotinamide adenine dinucleotide (NAD+).
NAD+ is crucial for cellular energy production and repair processes, and its levels naturally decline with age. The researchers found this decline to be even more pronounced in brains afflicted by Alzheimer’s, both in human tissue and in mouse models engineered to express human AD-linked mutations.
The key insight was that neurons suffering from NAD+ depletion lose the ability to maintain critical functions, contributing to widespread pathology. The researchers hypothesised that restoring NAD+ balance could therefore offer a route to not just slowing, but undoing disease progression.
Reversal of pathology and cognitive recovery in mice
To test this, the team administered P7C3-A20, a pharmacologic agent developed in the Pieper Laboratory that helps cells maintain proper NAD+ homeostasis under stress. Importantly, this compound does not simply flood cells with NAD+ (as over-the-counter precursors might), but stabilises normal balance to avoid unintended side effects.
The results were striking:
- In mice with advanced Alzheimer’s-like disease, delayed treatment with P7C3-A20 enabled the brain to “fix the major pathological events” caused by AD genetic mutations, according to a Case Western media release.
- Both lines of mice — one modelling amyloid pathology and the other tau pathology — fully recovered cognitive function after treatment, as assessed by behavioural testing.
- Treatment also normalised blood levels of phosphorylated tau 217, a clinical biomarker recently approved for Alzheimer’s diagnosis in humans, adding objective evidence of reversal rather than just symptom suppression.
Why this matters
“The key takeaway is a message of hope — the effects of Alzheimer’s disease may not be inevitably permanent,” said senior author Andrew A. Pieper, MD, PhD, director of the Brain Health Medicines Center at UH. “The damaged brain can, under some conditions, repair itself and regain function.”
That message is a potential game-changer. If human brains can recover function after significant disease progression, it could substantially alter drug development priorities, clinical trial design and investor expectations — shifting emphasis from incremental slowing of decline to meaningful functional recovery.
For biotech investors, the promise is clear: a successful translation of this strategy into humans could unlock a multibillion-dollar market and breathe new life into AD drug pipelines that have seen high-profile failures.
Caveats and the path ahead
Despite the excitement, there are important limitations. Animal models don’t perfectly mirror human Alzheimer’s, a nuanced and uniquely human disease. Efficacy in mice is not a guarantee of success in patients.
Notably, the compound used in this study works by maintaining energy balance — not by aggressively boosting NAD+ levels. Over-the-counter NAD+ precursors can raise levels excessively and have been shown in animal studies to promote cancer, a risk the authors explicitly note.
The researchers emphasised the need for “carefully designed human clinical trials to determine whether the efficacy seen in animal models translates to human patients”.
Bottom line
This research represents one of the most optimistic steps in Alzheimer’s science in years. While still early, and rooted in preclinical models, it highlights a new therapeutic angle — restoring brain energy homeostasis — that could, in time, redefine treatment goals.
For investors and biotech watchers, the next milestones to watch will be translation efforts, clinical trial initiation, and early safety/efficacy signals as this concept moves from bench to bedside.